Last reviewed · How we verify
NCT06137755
Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above
Phase 1 trial testing CVI-VZV-001 in Vaccine-Preventable Diseases in 32 participants. Currently enrolling.
21 March 2025
Quick facts
| Lead sponsor | CHA Vaccine Institute Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 32 |
| Start date | 15 March 2023 |
| Primary completion | 21 March 2025 |
| Estimated completion | 21 March 2025 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- CVI-VZV-001 — full drug profile →
- Shingrix (shingrix) — full drug profile →
Conditions studied
- Vaccine-Preventable Diseases — all drugs for Vaccine-Preventable Diseases →
- Herpes Zoster — all drugs for Herpes Zoster →
Sponsor
CHA Vaccine Institute Co., Ltd. — full company profile →
Who can join
Adults 50 to 64, any sex, with Vaccine-Preventable Diseases or Herpes Zoster. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06137755
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Vaccine-Preventable Diseases
Currently open trials in the same condition.
- NCT06978621 — Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV · Phase 3 · recruiting
- NCT06633835 — Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United St · Phase 4 · active not recruiting
- NCT06162676 — Game-Based Intervention to Promote HPV Vaccination · NA · active not recruiting
- NCT06088745 — A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine · Phase 3 · recruiting
- NCT05604911 — Herpes Virus Infections in Kidney Transplant Patients · active not recruiting
Other CHA Vaccine Institute Co., Ltd. trials
Trials by the same sponsor.
- NCT06147895 — A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Prophylactic Hepatitis B Vaccine · Phase 1 · completed
- NCT04289987 — A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine · Phase 2 · completed
- NCT02693652 — A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine · Phase 1, PHASE2 · completed
- NCT02692170 — A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06137755 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CHA Vaccine Institute Co., Ltd.
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06137755.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing